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Mutations inLRRK2are one of the primary genetic causes of Parkinson’s disease (PD). LRRK2 contains a kinase
and a GTPase domain, and familial PD mutations affect both enzymatic activities. However, the signaling
mechanisms regulating LRRK2 and the pathogenic effects of familial mutations remain unknown. Identifying
the signaling proteins that regulate LRRK2 function and toxicity remains a critical goal for the development of
effective therapeutic strategies. In this study, we apply systems biology tools to human PD brain and blood
transcriptomes to reverse-engineer aLRRK2-centered gene regulatory network. This network identifies several
putative master regulators of LRRK2 function. In particular, the signaling gene RGS2, which encodes for a
GTPase-activating protein (GAP), is a key regulatory hub connecting the familial PD-associated genes DJ-1
andPINK1with LRRK2 in the network. RGS2 expression levels are reduced in the striata of LRRK2 and sporadic
PD patients. We identify RGS2 as a novel interacting partner of LRRK2 in vivo.RGS2 regulates both the GTPase
and kinase activities of LRRK2. We show in mammalian neurons that RGS2 regulates LRRK2 function in the
control of neuronal process length. RGS2 is also protective against neuronal toxicity of the most prevalent
mutation in LRRK2, G2019S. We find that RGS2 regulates LRRK2 function and neuronal toxicity through its
effects on kinase activity and independently of GTPase activity, which reveals a novel mode of action for GAP
proteins. This work identifies RGS2 as a promising target for interfering with neurodegeneration due to
LRRK2 mutations in PD patients.
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INTRODUCTION
Mutations in the leucine-rich repeat kinase2 (LRRK2)gene have
emerged as the most common genetic determinant of Parkin-
son’s disease (PD), causing late-onset, familial autosomal dom-
inant PD and accounting for up to 40% of PD cases in certain
ethnic populations (1,2). LRRK2-associated PD is clinically
and neurochemically indistinguishable from sporadic PD. The
most prevalent mutation in LRRK2, G2019S, has also been
found in 1–2% of sporadic PD cases (2,3). Animal models dem-
onstrate that the G2019S mutation in LRRK2 can induce degen-
eration of dopaminergic (DA) neurons, which are the primary
target of neurodegeneration in PD (4,5). These findings
suggest that LRRK2 plays a pivotal role in the pathogenesis of
human PD.
LRRK2 is a large, multi-domain protein of 2527 amino acids. It
contains two catalytic domains, a kinase domain with highest se-
quence homology to mitogen-activated protein kinase kinase
kinase (MKKK) and receptor-interacting protein (RIP) kinase
families and a Ras-of-complex proteins (ROC) GTPase domain,
flanked by a C-terminal of ROC (COR) domain (6). In vitro,
LRRK2 can autophosphorylate and phosphorylate generic sub-
strates (e.g. myelin basic protein or LRRKtide) as well as a
range of putative substrates such as ArfGAP1, 4E-BP, moesin
andb-tubulin (7–11). However few, if any, of these putative sub-
strates have been broadly verified by multiple independent groups
and validated as authentic physiological substrates of LRRK2
kinase activity in vivo (12,13). All six mutations that clearly
segregate with disease occur in the kinase domain (G2019S and
I2020T), Roc GTPase domain (R1441C/G/H) or COR domain
(Y1699C) (6). These pathogenic mutations have been shown to
affect kinase and GTPase activities to varying degrees: the
R1441C/G/H and Y1699C variants impair GTP hydrolysis
without consistent effects on kinase activity, while the predomin-
ant G2019S mutation enhances kinase activity with no effect on
GTPase activity (6,14–18). Although the mechanisms remain
unclear, these findings suggest that both activities may play a
role in mediating neurodegeneration. Indeed, kinase activity is
required for the pathogenic effects of the G2019S mutation in
primary neurons and in rodents (5,6,17,19).
A number of studies have implicated LRRK2 in the regulation
of a wide variety of biological processes such as protein transla-
tion (20), cytoskeletal processes (9,21), vesicular dynamics (22),
response to mitochondrial damage (23) and autophagy (24,25).
This complexity of LRRK2 biology has made it extremely diffi-
cult to understand the contributions of the kinase and GTPase
domains to the function of LRRK2 (26). In particular, the up-
stream signaling mechanisms that control LRRK2 GTPase and
kinase activities and the pathogenic effects of familial mutations
remain unknown (26,27). Identifying the signaling proteins
that regulate LRRK2 function and toxicity remains a critical
outstanding goal for the development of effective therapeutic
strategies.
In the present study, we used an in silico approach to elucidate
the gene regulatory network linked to LRRK2. We applied a
network-based algorithm to reverse-engineer the LRRK2
network based on human PD blood and brain transcriptomes.
This work highlights in particular the role of the signaling
GTPase-activating protein (GAP) RGS2 as a key regulator of
LRRK2 activity, function and neuronal toxicity.
RESULTS
Elucidation of the LRRK2 regulatory network
The context likelihood of relatedness (CLR) algorithm is
designed to analyze state-dependent genome-wide expression
data based on the degree of synchrony of transcript levels,
using mutual information as a metric for scoring the similarity
between expression levels of two transcripts (28). CLR identifies
the component gene regulatory networks among large numbers
of subjects. We employed the CLR algorithm to analyze, in an
unbiased manner, a set of 119 publicly available array data
sets from the Substantia Nigra pars compacta (SNpc), frontal
cortex and whole blood of human PD patients and control
cases (29,30). Whole blood was included to enhance the input
of data from tissues that were not in terminal stages of degener-
ation. Recent studies support the utility of leukocytes for study of
PD by identifying putative PD biomarkers using blood transcrip-
tional profiles from LRRK2 G2019S carriers (30,31). Gene–
gene interactions were evaluated for statistical significance
using the Z-score metric, which is considered an alternative for
the t-test P-value metric. Interactions with a mutual information
Z-score ≥2.0 (corrected for background) were considered sig-
nificant. A LRRK2-centered association sub-network with first
and second neighbors was derived accordingly (Fig. 1A, Supple-
mentary Material, Fig. S1). Mutual information Z-scores
between individual gene nodes in the network are listed in Sup-
plementary Material, Table S1.
Members of the network regulatory map were grouped
to highlight the functional categories of the predicted LRRK2
interactors (Fig. 1A). The resulting LRRK2-centered network
correctly identified many of the genes/proteins previously asso-
ciated with LRRK2, including members of the Wnt signaling
pathway, the MAPK/ERK pathway such as MKK7 (MAP2K7)
and JIP1 (MAPK8IP1), beta tubulin (TUBB), FAS (which
binds to FADD, a documented LRRK2-binding protein) and
the PD-associated genes PARK2 (parkin), PINK1 and PARK7
(DJ-1) (Fig. 1A, Supplementary Material, Fig. S1 and
Table S1) (8,32–37). Many other genes in the LRRK2 regula-
tory network represent intriguing novel associations such as
EIF4G1, which is a first neighbor of LRRK2 and encodes for a
key component of the protein translation machinery, or BCL2L1,
also a LRRK2 first neighbor and member of the BCL-2 family of
apoptosis regulators.Genessuchasactin (ACTA1), and theWntsig-
naling members FZD1 and TNKS are connected to large groups of
secondary regulatory neighbors, and are highlighted in the network
as regulatory ‘hubs’ (Fig. 1A, Supplementary Material, Fig. S1).
The resulting network highlights the diversity of processes that
coordinate with LRRK2, including processes important for syn-
aptic transmission, cytoskeletal function, RNA processing,
mitochondrial function and autophagy (Fig. 1A).
Identification of regulatory network genes that modify
LRRK2 function in vivo
The MNI and CLR analyses identified 181 C. elegans and 200
human genes whose expression levels are highly coordinated
with those of LRRK2. To determine the extent to which these
genes modify the function of LRRK2 in vivo, we performed an
RNAi high-throughput screen utilizing C. elegans.
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We had previously determined that DA neurons inC. elegans
are selectively sensitive to rotenone toxicity, showing neuronal
death at doses 100-fold less than doses required to kill nematodes
(23). This work also demonstrated that LRRK2 significantly pro-
tectsC. elegans and, in particular, DA neurons, against rotenone
toxicity (23). We utilized the neuroprotection phenotype as a
screening platform to evaluate the contribution of the systems
biology predicted interactors to LRRK2 function (Fig. 2A).
Caenorhabditis elegans expressing wild-type human LRRK2
driven by the pan-neuronal synaptobrevin promoter (snb::
LRRK2) and eGFP driven by the dopamine transporter promoter
(dat-1::GFP) were used as a platform for the screen (23). The
Figure 1. Reverse-engineering of the LRRK2 gene regulatory network. (A) The CLR algorithm was applied to genomic profiling data from human PD patients and
control cases to generate an in silico LRRK2 gene regulatory network. Genes among the LRRK2 centered network represent 16 functional groups. See also Supple-
mentary Material, Figure S1 and Table S1. (B)LRRK2 centered sub-network focused on the PD genes:PINK1,DJ-1 andPARKIN. PD-linked genes are represented in
pink.Genes shown in blue represent first neighbors, green represents second neighbors, yellow colored genes identifygenes (or proteins) that were previously shown to
be associated with LRRK2 or genes highlighted by this study; many of the yellow-colored genes are also LRRK2 first neighbors. See also Supplementary Material,
Table S2.
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Figure 2. Validation of LRRK2 network interactors. (A) RNAi targeted to the putative LRRK2 interactors were fed to WT LRRK2 expressing C. elegans, and DA
survival in the presence of rotenone was quantified. (B) Algorithm to quantify the effects of RNAi by imaging GFP expression in the DA neurons. Scoring: 3, the
cell body and dendrite were intact and similar to untreated nematodes; 2, a shrunken cell body or a loss of dendritic processes; 1, loss of or barely visible dendritic
process and cell body. Hits were defined as survival outside two standard deviations from the control RNAi. (C) Representative effects of genes that modify DA
neuron survival.
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RNAi hypersensitivity mutation, rrf-3 (pk1426), was introduced
to enhance the sensitivity of the neurons to RNAi. No observable
phenotypic changes were observed upon introduction of the rrf-3
mutation, and the LRRK2-mediated protection phenotype was
replicated (Supplementary Material, Fig. S2A). We screened a
set of genes generated from the MNI and CLR analyses. A PSI
blast of the 200 genes from the human CLR network was used
to identify 506 putative C. elegans orthologs. This set was com-
bined with the 181 nematode genes identified in the MNI ana-
lysis, yielding a total of 687 genes for the C. elegans study.
The LRRK2 nematodes were synchronized by egg-laying on
plates carrying individual RNAi vectors targeted to the regula-
tory network genes. Larval stage four nematodes were then
treated with rotenone for 24 h, and the survival of their dopamin-
ergic neurons evaluated by visualizing GFP expressed in the DA
neurons (Fig. 2A). We devised a scoring system that took into
account the number of neurons and their morphology
(Fig. 2B). Previous work demonstrated a strong correlation
between dat-1::GFP and DA neuron survival, and determined
that the CEP and ADE DA neurons are selectively sensitive to
PD-associated neurotoxins (38, 39). Replicated measurements
with an empty RNAi vector, PL4440, indicated that the
scoring system had a low baseline fluctuation. RNAi that signifi-
cantly altered the DA neuron survival outside of two standard
deviations from the empty vector control were considered hits
of the screen. Selected RNAi constructs were sequenced and
found to be specific for the predicted target gene and did not
exhibit significant off-target effects (Supplementary Material,
Fig. S2B and C).
The cumulative results indicated that 280 (40%) of the systems
biology predicted genes alteredLRRK2-mediated DA neuron sur-
vival. The validated systems biology candidates were distributed
across the LRRK2-centered PD network (Supplementary Mater-
ial, Table S3). Seventy-one percent of the validated candidates
decreased DA neuron survival, while 29% increased survival.
The hits were annotated using Wormbase and GO analysis
(Supplementary Material, Table S3). The ‘autophagy/endosomal/
lysosomal’ and the ‘Parkinson’s disease related’ groups
consistently exhibited strong negative effect sizes with 251
and 243%, respectively (Fig. 2C, Supplementary Material,
Table S3). The autophagy-related genes, including unc-51,
vps-34 (VPS34, PIK3C3), vps-33.1, hda-6 (HDAC6), ctns-1,
num-1 and unc-57, showed a consistent inhibitory effect on the
protection phenotype, with the largest effect evident for knock-
down of vps-34 (PIK3C3). The 81% reduction of DA neuron
survival observed upon knockdown of vps-34(PIK3C3) was
one of the strongest decreases of DA neuron survival in the
C. elegans LRRK2 line (Fig. 2C, Supplementary Material,
Table S3). These results suggest that protection by WT LRRK2
requires normal autophagic function.
In contrast, the ‘NFkB/TGFbeta/WNT’ and ‘Axon Guidance/
Cytoskeleton’ groups had the largest positive effect sizes with 22
and 18%, respectively (Supplementary Material, Table S3); the
smaller average effect sizes reflect the interaction of positive and
negative effectors in these groups. It is interesting to note that
knockdown of transcripts in the mitochondrial gene category
improved survival, while knockdown of the PD-associated
genes djr-1.1(DJ-1), pdr-1(PARKIN) and pink-1(PINK1) resulted
in 243, 249 and 238% decreases in DA neuron survival, re-
spectively (Fig. 2C, Supplementary Material, Table S3). Previous
work has identified functional interactions between all four of
PD-linked genes, which supports the current results and suggests
that these genes function together in an integrated PD gene
network (37) (Fig. 2C).
Genes associated with MAPK signaling have been highly
implicated in LRRK2 function. Knockdown ofMAPK signaling
genes, including jkk-1 (MAP2K7), mek-2 (MAP2K2) and mpk-1
(MAPK1) reduced DA neuronal survival by 225, 247 and
269%, respectively (Supplementary Material, Table S3). This
replicates findings from our group and others showing a strong
interaction between MKK6 (MAP2K6), MKK7 (MAP2K7),
ERK (MAPK) and JNK (MAP2K8) in LRRK2 function (32, 34,
35, 40, 41). Another kinase implicated in neurodegenerative pro-
cesses, cdk-5 (CDK5), also exhibited strong effects. Knockdown
of cdk-5 enhanced neuron survival by 99% (Supplementary
Material, Table S3).
We identified novel putative LRRK2 interactions as well. The
gene, mom-5 (FZD1), shows a striking role as a hub in the
LRRK2 regulatory network, and knockdown of FZD1 increased
DA neuron survival by 49% (Fig. 1A, Supplementary Material,
Table S3). This result mirrors a recent study identifying FZD2
as a central regulator of progranulin function (42). Other WNT
genes, such as cwn-1 (WNT4) and cfz-2 (FZD9), strongly
reduced DA neuron survival upon knockdown (275 and
252%, respectively, Supplementary Material, Table S3).
There were 12 G protein signaling genes, including the regula-
tors of G protein signaling, rgs-2, rgs-6, rgs-8.1 and eat-16.
These genes showed differential regulation; inhibition of rgs-2
(RGS1,RGS2) and rgs-6 (RGS1,RGS2) enhanced DA neuron sur-
vival by +20–30%, while inhibition of rgs-8.1 and eat-16
decreased DA neuron survival by240 to250%. (Fig. 2C, Sup-
plementary Material, Table S3).
We investigated whether the effects of knockdown would be
the same with a different assay. We examined the effects of
selected genes using a thrashing assay, which is a phenotype
strongly influenced by synaptic function. We examined five
genes linked to autophagy: parkin, pink-1, hda-6, atp6a2 as
well as lrk-1. Knockdown of four of the genes did not alter
thrashing to extents that were significantly different (% change
in thrashing versus vector: parkin, 2.9+ 2.7; pink-1, 8.3+
2.5; atp6a2, 14.5+ 3.1; lrk-1, 3.0+ 2.7). Knockdown of
hda-6 decreased thrashing by 40.1+ 8.1%. This indicates that
the effects on DA neuron survival can be quite specific for
neuroprotection.
Endogenous lrk-1 is required for effects on DA neuron
survival in C. elegans
The strong effects of genes linked to autophagy on DA neuron
survival in the LRRK2 C. elegans line prompted us to examine
whether these genes required LRRK2/lrk-1 for their actions.
We focused on vps-34, unc-51 and hda-6 because these are
particularly important regulators of the autophagic-lysosomal
degradation pathway (5,43,44). Repeat experiments validated
that the knockdown of vps-34 leads to a significant reduction
in survival score compared with empty vector treated
LRRK2-expressing C. elegans (P, 0.0001) (Fig. 3A). Knock-
down of vps-34 in the lrk-1(km17) exhibited an inverse
effect on DA neuron survival, significantly enhancing survival
compared with empty vector control (P , 0.05) (Fig. 3A).
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Knockdown of unc-51 also produced a significant reduction
in survival score compared with empty vector treated LRRK2-
expressing C. elegans (P , 0.05) (Fig. 3B), consistent with
the results of our initial screen. Knockdown of unc-51 in the
lrk-1(km17) strain did not modify DA neuron survival beyond
that observed with lrk-1(km17) alone (Fig. 3B).
We also examined RGS2, which is abundant in dopaminergic
neurons, and is decreased in the striatum of D1 receptor knockout
mice (45, 46). Yeast two hybrid studies also show an interaction
between RGS2 and parkin (47). The enhanced DA neuron pro-
tection produced by knockdown of rgs-2 was replicated in the
LRRK2-expressing C. elegans line following treatment with
rgs-2 RNAi (P , 0.05) (Fig. 3C). Protection mediated by rgs-2
knockdown required the presence of LRRK2/lrk-1; knockdown
of rgs-2 did not cause a significant change in the lrk-1(km17)
strain, which has a deletion in the endogenous ortholog of
LRRK2 (Fig. 3C). These data suggest that rgs-2 modulates
LRRK2/lrk-1 function, and that the two genes act through the
same pathway.
Interaction of LRRK2 with RGS2 in mammalian cells
and in vivo
Having validated the role of RGS2 in LRRK2 function in
C. elegans, we proceeded to explore its interactions with
LRRK2 in mammalian systems. We first examined the capacity
of RGS2 to bind LRRK2 by co-immunoprecipitation (IP) of
overexpressed proteins in HEK293T cells. Following IP of
FLAG-LRRK2, we found a robust interaction with full-length
HA-RGS2 (Fig. 4A). PD-associated mutations in LRRK2
(G2019S, R1441C and Y1699C) had no effect on the strength
of the interaction (Fig. 4A). In the reverse IP, Myc-LRRK2 inter-
acted with immunoprecipitated HA-RGS2 (Fig. 4B). We next
validated the interaction of endogenous LRRK2 and RGS2
in vivo, by showing that RGS2 is co-immunoprecipitated
with endogenous LRRK2 from mouse striatal tissue (Fig. 4C).
We then examined the domain requirements for association of
LRRK2 and RGS2. RGS2 was overexpressed with LRRK2 con-
structs coding for individual functional domains (Fig. 4D). Fol-
lowing IP of LRRK2 deletion constructs, we found that RGS2
interacts most strongly with residues 480–895 of LRRK2, a
region containing LRRK2-specific repeats (residues 1–660),
armadillo repeats (residues 180–660) and putative ankyrin
repeats (residues 690–860) known to mediate protein–protein
interactions (Fig. 4D). Conversely, we wanted to establish the
domain of RGS2 with which LRRK2 interacts. RGS2 contains
a core domain of 130 amino acids, which is responsible for
its GAP activity and a 78-amino-acid N-terminal domain,
which mediates its selective binding to specific G protein-
coupled receptors (GPCRs) to modulate linked G protein
signaling (48) (Fig. 4E). We overexpressed FLAG-LRRK2
with full-length RGS2 or a truncated version of the protein
lacking the first 78 amino acids (DN-RGS2) (Fig. 4E). Expres-
sion levels of DN-RGS2 were lower compared with the full-
length protein, presumably because of the importance of the
N-terminal domain in stabilizing the protein (49). Following
IP of FLAG-LRRK2, we found that truncated DN-RGS2 was
still able to interact with LRRK2 (Fig. 4E). This suggests that
RGS2 most likely binds to LRRK2 via its GAP domain.
Finally, we assessed the co-localization of both proteins in mam-
malian cells by confocal microscopy. Consistent with previous
reports (48,50), we found that RGS2 exhibits a ubiquitous and
diffuse distribution in the nucleus and cytoplasm, whereas
LRRK2 is also diffusely expressed in the cytoplasm but excluded
from the nucleus (Supplementary Material, Fig. S4). Upon
co-expression, although both proteins do not uniformly
co-localize in the cytoplasm, we identified multiple areas of
co-localization in all visualized HEK cells and primary
neurons, which likely account for the biochemical and functional
interactions identified between LRRK2 and RGS2 (from three
independent experiments, n ¼ 10 HEK cells and neurons
visualized/experiment) (Supplementary Material, Fig. S4). No
obvious changes in the cellular localization of either protein
were observed upon co-expression compared with expression
of either protein alone (data not shown). It was not possible to re-
liably assess co-localization of endogenous RGS2 and LRRK2
with currently available antibodies because of insufficient speci-
ficity when used for immunocytochemistry.
RGS2 regulates the GTPase and kinase activities of LRRK2
RGS2 is known to function as a GAP protein, acting as negative
modulator of GPCR signaling by stimulating the GTPase activ-
ity of the a subunits of G proteins (48). We therefore examined
Figure 3. LRK-1 deletion studies. (A) Knockdown of vps-34 (RNAi) significantly reduced DA neuron survival in WT LRRK2/dat-1::GFP/rrf3(pk1426) nematodes,
but increased survival in the lrk-1 [km-17] deletion line. The data for (A)–(C) are normalized to the results for pDAT::GFP nematodes grown under basal conditions.
(B) Knockdown of unc-51(RNAi) significantly reduced DA neuron survival in the WT LRRK2/dat-1::GFP/rrf3(pk1426) line, but had no effect on the km-17.
(C) Quantification showing a significant increase in DA survival score upon knockdown of rgs-2 (RNAi) in LRRK2 expressing C. elegans (P, 0.05). Inhibition
of rgs-2 in the km17 strain does not cause a significant change in survival, indicating an effect specific to LRRK2 function.
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whether RGS2 may also regulate the GTPase activity of LRRK2.
Recombinant RGS2 increased the GTPase activity of immu-
nopurified full-length LRRK2 in a dose-dependent manner
in vitro (Fig. 5A, left panel). Recombinant RGS2 itself lacks in-
trinsic GTPase activity (Fig. 5A, right panel). We next monitored
the effects of RGS2 on steady-state levels of GTP-bound LRRK2
in vivo. We conducted GTP-sepharose pull-down assays on
HEK293T cell extracts expressing Myc-LRRK2 in the presence
or absence of HA-RGS2. We found that RGS2 did not affect the
steady-state levels of GTP-bound WT or mutant (R1441C and
G2019S) LRRK2 (Fig. 5B). The specificity of the assay was
demonstrated by showing that the K1347A mutant, which
abolishes binding to guanine nucleotides (51), is not pulled
down by the GTP-sepharose, and that excess amounts of free
GTP compete for binding and eliminate precipitation of
LRRK2 (Fig. 5C).
We then assessed the effects of RGS2 on the kinase activity of
LRRK2. We found that recombinant RGS2 inhibited kinase ac-
tivity of full-length LRRK2 in vitro in a dose-dependent manner
(Fig. 5D). Analysis of the dose–response curves for RGS2
modulation of LRRK2 enzymatic activities shows that RGS2
achieves maximal inhibition of LRRK2 kinase activity (50%
inhibition) at a dose of RGS2 that is at least one-tenth the dose
required to maximally stimulate GTPase activity (i.e. RGS2:
LRRK2 ratios of 1 versus .10, Fig. 5D versus Fig. 5A). We
also found that RGS2 was unable to modulate the activity of
truncated LRRK2 (970–2527 amino acids) (data not shown), in-
dicating a requirement for full-length LRRK2, which is consist-
ent with RGS2 binding most strongly with residues 480–895 of
LRRK2 (Fig. 4D). Inhibition of LRRK2 kinase activity was veri-
fied by examining LRRK2 autophosphorylation sites. Lysates of
HEK 293 cells expressing V5-LRRK2+RGS2 were probed
with antibodies against LRRK2 (anti-V5), or phosphospecific
LRRK2 antibodies (Fig. 5E). Phosphorylation of LRRK2 at
Ser910 was reduced by co-expression with RGS2 (Fig. 5E),
consistent with the in vitro results from Figure 5D. In contrast,
phosphorylation at Ser935 was not affected (Fig. 5E). Immuno-
purified full-length LRRK2 was therefore used in an in vitro
assay to establish whether RGS2 is also a substrate for the
kinase activity of LRRK2. We found that full-length WT
LRRK2 could robustly phosphorylate recombinant RGS2
(Fig. 5F). The specificity of the assay was demonstrated by
showing that phosphorylation of RGS2 was enhanced by the
kinase-hyperactive G2019S mutation, whereas a kinase-dead
Figure 4. Interaction of LRRK2 with RGS2 in mammalian cells and in vivo. (A) Overexpressed HA-RGS2 interacts with WT and mutant (R1441C and G2019S)
FLAG-LRRK2, following IP with anti-FLAG antibody from HEK293T cells. (B) In the reverse IP, wild-type Myc-LRRK2 interacts with HA-RGS2 following IP
with anti-HA antibody from HEK293T cells. (C) Endogenous RGS2 interacts with LRRK2 in mouse cerebral cortex following IP with anti-LRRK2 antibody but
not with a rabbit IgG control. IgG heavy chain (HC) indicates the equivalent amounts of IgG used for IP. (D) HA-RGS2 was overexpressed with individual WT
LRRK2 deletion constructs in HEK293T cells. Immunobloting for HA-RGS2 following IP with anti-FLAG antibody revealed that RGS2 interacts most strongly
with the F2 fragment containing residues 480–895. Domain organization of LRRK2 deletion constructs is indicated. (E) Full-length WT FLAG-LRRK2 was over-
expressed in HEK293T cells with either full-length WT RGS2-HA (25 kDa) or N-terminally truncated RGS2-HA (DN-RGS2-HA, 16 kDa). Following IP of
FLAG-LRRK2, we found an interaction with both full-length and truncated RGS2, suggesting that LRRK2 interacts with the GAP domain of RGS2. Domain organ-
ization of RGS2 constructs is indicated. Data are representative of at least two independent experiments. See also Supplementary Material, Figure S4.
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LRRK2 variant (D1994A) had negligible effects on RGS2 phos-
phorylation (Fig. 5F). Finally, the oligomerization/dimerization
state of LRRK2 has been shown to be a critical determinant of the
kinase activity of the protein (52). To investigate whether RGS2
affects the oligomerization of LRRK2, we ran native PAGE gels
of HEK293T cell extracts expressing Myc-LRRK2 in the pres-
ence or absence of RGS2 (Supplementary Material, Fig. S5).
We found that the high-molecular weight distribution and dimer-
ization of wild-type or mutant (R1441C and G2019S) LRRK2
was similar in the presence or absence of RGS2 (Supplementary
Figure5.RGS2 regulates the GTPase and kinase activities of LRRK2. (A) Recombinant RGS2 increases the GTPase activity of immunopurified full-length LRRK2 in
a dose-dependent manner, as measured by the production ofa-32P-GDP in thea-32P-GTP hydrolysis reaction (VimM/min). Recombinant RGS2 was pre-incubated at
various concentrations with 32 nM of immunopurified full-length WT LRRK2 to give increasing ratios of [RGS2]/[LRRK2]. Background reaction was conducted in
the absence of LRRK2. Recombinant RGS2 itself lacks intrinsic GTPase activity. Reactions were conducted in triplicate. Error bars represent SEM. (B) RGS2 does not
affect the steady-state levels of GTP-bound WT or mutant (R1441C and G2019S) LRRK2, as indicated by GTP-sepharose pull-down assays on HEK293T cell extracts
expressing Myc-LRRK2 in the presence or absence of HA-RGS2. (C) The GDP/GTP binding-deficient K1347A mutant is not pulled down by the GTP-sepharose and
excess amounts of free GTP (2 mM) compete for binding and eliminate precipitation of LRRK2 in the presence or absence of RGS2. (D) In vitro kinase activity assay
with g-32P-ATP showing that recombinant RGS2 inhibits kinase activity of full-length LRRK2 in a dose-dependent manner, as measured by scintillation counting of
LRRKtide peptide phosphorylation. Background reaction was conducted in the absence of LRRK2. Recombinant RGS2 was pre-incubated at various concentrations
with 100 nM of immunopurified full-length WT LRRK2 to give increasing ratios of [RGS2]/[LRRK2]. Reactions were conducted in duplicate. Error bars represent
SEM. (E) HEK cells were transfected with V5-LRRK2 (WT)+RGS2. Lysates were collected and probed for total LRRK2 (anti-V5, left panel), RGS2, actin,
phospho-Ser910-LRRK2 (middle panel) and phospho-Ser935-LRRK2 (right panel). Only phospho-Ser910-LRRK2 was reduced by co-expression with RGS2.
(F) 32P autoradiograph shows the robust phosphorylation of recombinant GST-RGS2 by full-length WT LRRK2. Phosphorylation is further enhanced by the
kinase-hyperactive G2019S mutation, whereas a kinase-dead LRRK2 variant (D1994A) has negligible effects on RGS2 phosphorylation. Immunoblot of input
levels of recombinant GST-RGS2 and full-length LRRK2 variants immunoprecipitated from HEK 293T cells shows equal loading for each condition. LRRK2
autophosphorylation was also detected in this assay. ∗ denotes a non-specific band. Data are representative of at least two independent experiments. See also
Supplementary Material, Figure S5.
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Material, Fig. S5). Taken together, these results show that RGS2
regulates both the GTPase and kinase activities of LRRK2,
without affecting the oligomeric structure of the protein.
RGS2 protects against G2019S LRRK2-induced neurite
shortening and neuronal toxicity
LRRK2 regulates neuronal process length and complexity in
primary neurons with silencing or knockout of LRRK2 increas-
ing neurite length and branching, whereas overexpression of the
PD-associated G2019S LRRK2 mutant induces neurite shorten-
ing and concomitant neuronal toxicity (9,10,53). We therefore
investigated the effects of RGS2 expression on G2019S
LRRK2-induced neurite shortening and toxicity. Mouse
primary cortical neurons were transfected at days-in-vitro
(DIV) 5 with empty vector control, wild-type LRRK2 or
G2019S LRRK2 in the presence or absence of overexpressed
RGS2. We observed no changes in myc-LRRK2 (WT or
G2019S) or HA-RGS2 expression levels upon co-expression of
both proteins, compared with levels of either protein expressed
alone (Fig. 6A). A GFP-expressing plasmid was co-transfected
in each condition to morphologically label transfected neurons
(LRRK2/RGS2/GFP; 10:10:1 molar ratio). Double- or triple-
immunolabeling with overexpressed myc-LRRK2 and HA-RGS2
was confirmed in.95% of GFP-positive neurons (Supplementary
Material, Fig. S6A). Neurons were subsequently fixed at DIV20
and immunolabeled for GFP (Fig. 6B). For neurite length
measurements, we determined the length of the longest neurite
process of individual GFP-labeled neurons, corresponding to
the axon. Neurite length analysis was restricted to MAP2-positive
neurons, in which axons could be distinguished from dendrites
by the absence of MAP2 staining (Supplementary Material,
Fig. S6B). Consistent with previous observations, we found
that G2019S LRRK2 induced a robust shortening of axonal
processes relative to empty vector control, with a smaller but
still significant effect of WT LRRK2 (Fig. 6B and C). We
found that RGS2 robustly protected against the effects of the
G2019S mutant and could also rescue WT LRRK2-induced
axonal shortening (Fig. 6B and C). RGS2 expression alone
had no effect on axonal length (Fig. 6C). Next, to determine
whether neuronal toxicity occurred concomitant to neurite short-
ening in our model, we assessed the viability of transfected
GFP-positive neurons at DIV20. Neurons with no obvious pro-
cesses or processes shorter than twice the size of the cell body
were counted as non-viable (Fig. 6D). Expression of G201S
LRRK2 resulted in significant neuronal toxicity, which was
rescued by co-expression of RGS2 (Fig. 6D and E). RGS2 expres-
sion alone had no effect on neuronal viability relative to control
(Fig.6D and E).Taken together, these results showthatRGS2pro-
tects against G2019S LRRK2-induced neurite shortening and
neuronal toxicity.
Silencing of RGS2 induces neurite shortening in a
LRRK2-dependent manner
Having shown that RGS2 overexpression could protect against
mutant LRRK2-induced neurite shortening, we then investi-
gated whether endogenous RGS2 played a role in the regulation
of neurite process length. We first tested plasmids expressing
short hairpin RNAs (shRNAs) targeted against mouse RGS2
for their ability to silence mouse HA-RGS2 overexpressed in
HEK293T cells, relative to a non-silencing control shRNA
plasmid carrying a ‘scramble’ sequence (sh-scramble) (Supple-
mentary Material, Fig. S7A). The sh-RGS2 sequence #3 was
found to highly efficiently silence mouse RGS2 (Supplementary
Material, Fig. S7A) and was chosen for all subsequent experi-
ments. We also chose a sh-LRRK2 construct, which was previ-
ously shown by western blot to efficiently silence mouse
LRRK2 (54). Mouse primary cortical neurons were then trans-
fected at DIV5 with combinations of sh-scramble, sh-RGS2
and sh-LRRK2 plasmids (Fig. 7A). As above, a GFP plasmid
was co-transfected in each condition to morphologically label
transfected neurons. Neurons were fixed at DIV20 and immuno-
labeled for GFP. We found that silencing of endogenous RGS2
led to a significant reduction in axonal length relative to the
control group transfected with sh-scramble only (Fig. 7A and B).
This effect was no longer visible upon co-silencing of LRRK2
(Fig. 7A and B), which, by itself, promoted a significant increase
in axonal length (Fig. 7A and B), as previously reported (9,53).
These data therefore identify a novel cellular function for
RGS2 in the control of neurite length, which is dependent on
LRRK2.
Synergistic effect of RGS2 silencing on LRRK2-induced
neurite shortening is dependent on LRRK2 kinase activity
Since silencing of endogenous RGS2 promotes neurite shorten-
ing in a LRRK2-dependent manner, we now sought to directly
investigate the effect of RGS2 silencing on LRRK2-induced
neurite shortening. Lentiviral vectors (LV) were produced
based on the sh-scramble and sh-RGS2 silencing constructs
described above. We confirmed by western blot analysis that
LV-sh-RGS2 efficiently silenced endogenous mouse RGS2 in
primary mouse neurons with no effect on endogenous LRRK2
levels (Supplementary Material, Fig. S7B). Primary cortical
neurons were then infected with LV-sh-scramble and LV-
sh-RGS2 at DIV3, followed by co-transfection at DIV5 with
empty vector control or WT LRRK2 and GFP at a 10:1 molar
ratio. WT LRRK2 rather than G2019S LRRK2 was used in this
experiment in order to assess more subtle effects resulting from
concomitant silencing of RGS2. Neurons were fixed at DIV20
and immunolabeled for GFP. Consistent with our previous obser-
vations (Figs 6B and C and 7A and B), overexpression of WT
LRRK2 and silencing of RGS2 alone each led to significant
decreases in axonal length relative to the control LV-sh-scramble
group (12 and 16% respectively, Fig. 7C). However, when
WT LRRK2 was expressed in the presence of reduced levels of
RGS2, axonal length was reduced to an extent (44%) greater
than would be expected from a simple additive effect of both
insults (28%) (Fig. 7C). A synergistic effect between both
factors was confirmed by two-way factorial ANOVA analysis
(WT LRRK2 overexpression X RGS2 silencing, P, 0.001).
These data therefore show that silencing of RGS2 has a significant
synergistic effect on WT LRRK2-induced neurite shortening.
Next, to test whether the synergistic effect of RGS2 silencing
on LRRK2-induced neurite shortening is dependent on LRRK2
kinase activity, we looked at the combined effects of RGS2 silen-
cing with overexpression of a kinase-inactive K1906M LRRK2
variant, which is stable when overexpressed in primary neurons
(Supplementary Material, Fig. S7C). Overexpression of K1906M
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LRRK2 by itself had no effect on axonal length relative to the
control LV-sh-scramble group (Fig. 7D). Silencing of RGS2
alone reduced axonal length by15% (Fig. 7D). No synergistic
effects were produced by silencing RGS2 and overexpressing
K1906M LRRK2 together (Fig. 7D). These findings therefore
suggest that the synergistic effect of RGS2 silencing on LRRK2-
induced neurite shortening is dependent on kinase activity of
LRRK2.
Figure 6. RGS2 protects against G2019S LRRK2-induced neurite shortening and neuronal toxicity. (A) Western blot analysis with anti-myc (LRRK2), anti-HA
(RGS2) and anti-actin antibodies of cell extracts of mouse cortical neurons harvested at DIV20 following transfection with indicated constructs at DIV5. No
changes in myc-LRRK2 (WT or G2019S) or HA-RGS2 expression levels were observed upon co-expression of both proteins, compared with levels of either
protein expressed alone. (B) Mouse primary cortical neurons were transfected at DIV5 with empty vector control or Myc-LRRK2 (WT or G2019S), HA-RGS2
and GFP at a 10:10:1 molar ratio and fixed at DIV20. Fluorescence microscopy with anti-GFP antibody allows labeling of cell body and neuritic processes of trans-
fectedneurons. Arrows indicate the neuronal soma and arrowheadsmark the axonalprocesses.Photomicrographs are representative of three independent experiments/
cultures. Scale bar: 200 mm. (C) Measurement of the length of GFP-labeled longest neuritic processes, i.e. axons, reveals that G2019S LRRK2 induces a significant
shortening of axonal process relative to empty vector control, with a smaller but significant effect of WT LRRK2. RGS2 rescues WT LRRK2-induced neurite short-
ening and robustly protects against the effects of the G2019S mutant. RGS2 expression alone has negligible effects on axonal length relative to control, ∗∗∗P, 0.001,
∗∗P , 0.01, ∗P , 0.05, by one-way ANOVA with the Newman–Keuls post hoc analysis. ns, non-significant. Bars represent the mean+SEM, from three independ-
ent experiments, with n ¼ 30–45 neurons measured/experiment. (D) Representative photomicrographs of the viability of GFP-positive neurons at DIV20 following
transfection with indicated constructs at DIV5. Representative photomicrographs of the viability of GFP-positive neurons at DIV20 following transfection with indi-
cated constructs at DIV5. Neurons with no obvious processes or processes shorter than twice the size of the cell body were counted as non-viable. Arrows indicate
neurons counted as non-viable. Scale bar: 100 mm. (E) Quantification of the number of viable transfected neurons as a % of total transfected neurons. Bars represent the
mean+SEM, from three independent experiments, withn ¼ 150–200 transfected neurons counted/experiment. RGS2 overexpression protects against neuronal tox-
icity induced by G2019S LRRK2. ∗P , 0.05, by one-way ANOVA with the Newman–Keuls post-hoc analysis. See also Supplementary Material, Figure S6.
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Levels of RGS2 are reduced in mutant G2019S LRRK2 and
sporadic PD brains
Since changes in expression levels of RGS2 (overexpression and
silencing) modulate LRRK2-induced neurite shortening and
neuronal toxicity, we investigated whether aberrant RGS2
expression could be found in the brains of LRRK2 patients.
We observed that protein levels of RGS2 were significantly
reduced in caudate striatal tissue of mutant G2019S LRRK2
PD patients compared with neurologic controls (Fig. 8A). We
also observed reduced RGS2 expression levels in striatal tissue
of sporadic PD patients compared with controls (Fig. 8B). To-
gether, these data implicate RGS2 in the pathophysiology of
human PD.
DISCUSSION
The regulatory mechanisms controlling the activity and toxicity
of LRRK2 remain poorly understood. In this study, we
Figure 7. Silencing of RGS2 induces neurite shortening in a LRRK2-dependent manner and has a kinase-dependent synergistic effect on LRRK2-induced neurite
retraction. (A) Mouse primary cortical neurons were transfected at DIV5 with either sh-scramble alone (control group), sh-scramble + sh-RGS2, sh-scramble +
sh-LRRK2 or sh-RGS2 + sh-LRRK2 plasmids combined with GFP at a 10:10:1 molar ratio. Neurons were fixed at DIV20. Note that sh-scramble was co-transfected
with sh-RGS2 or sh-LRRK2 to keep the levels of transfected DNA constant. Photomicrographs are representative of three independent experiments/cultures. Scale
bar: 200 mm. (B) Silencing of endogenous RGS2 (sh-scramble + sh-RGS2) leads to a significant reduction in axonal length relative to the control group transfected
with sh-scramble only. In contrast, RGS2 silencing no longer had a significant effect on axonal length upon co-silencing of LRRK2 (sh-RGS2 + sh-LRRK2 compared
with sh-scramble + sh-LRRK2). LRRK2 silencing alone promoted a significant increase in axonal length relative to the sh-scramble control group. ∗P , 0.05, by
one-way ANOVA with the Newman–Keuls post-hoc analysis. ns, non-significant. Bars represent the mean+SEM, from three independent experiments, with
n ¼ 30–45 neurons measured/experiment. (C) Mouse primary cortical neurons were infected with LV-sh-scramble or LV-sh-RGS2 at DIV3, followed by transfection
at DIV5 with empty vector control or WT LRRK2 combined with GFP at a 10:1 molar ratio. Neurons were fixed at DIV20. Overexpression of WT-LRRK2 alone
(LV-sh-scramble + WT-LRRK2 group) and silencing of RGS2 alone (LV-sh-RGS2) led to a significant retraction of axons compared with the LV-sh-scramble
control group. Expression of WT LRRK2 in the presence of RGS2 silencing (LV-sh-RGS2 + WT LRRK2) induced a significant synergistic shortening of axons
as determined by the two-way factorial ANOVA analysis (WT LRRK2 overexpression × RGS2 silencing, ∗∗∗P , 0.001). (D) The kinase-inactive K1906M
LRRK2 variant by itself has negligible effects on axonal length. Silencing of RGS2 alone reduced axonal length by 15%. No synergistic effects were produced
by overexpressing K1906M LRRK2 in the presence of RGS2 silencing. ∗∗∗P, 0.001, ∗∗P , 0.01 ∗P, 0.05, by two-way ANOVA with the Newman–Keuls
post hoc analysis. Bars represent the mean+SEM, from three independent experiments, with n ¼ 30–45 neurons measured/experiment. See also Supplementary
Material, Figure S7.
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implemented ‘top–down’ systems biology methods to human
PD brain and blood transcriptomes to generate a PD LRRK2-
centered gene regulatory network. This regulatory network pro-
vides a roadmap for understanding the signaling context of each
LRRK2 interacting gene. This in silico approach has a high
degree of face validity because it correctly highlights many
of the genes/proteins previously shown to interact with LRRK2,
including beta-tubulin (TUBB), FAS, proteins associated with
MAPK signaling such as MKK7 (MAP2K7) or JIP1 (MAPK8IP1),
and members of the Wnt signaling pathway. We also identify
many novel regulators of LRRK2 function, positioned as ‘hubs’
in the network connected to large groups of secondary neighbors,
including Actin (ACTA1) and the Wnt signaling members FZD1
and Tankyrase-1 (TNKS). Our network also includes members
that are genetically linked to PD, including parkin, PINK1 and
DJ-1. Further validation was evident through the knockdown
studies in nematodes, which demonstrated functional effects
on survival of dopaminergic neurons in C. elegans expressing
LRRK2 for over 280 of the predicted network genes. These pre-
dictions included each of those mentioned above. By focusing on
this sub-network of PD-linked genes, we identify the signaling
gene RGS2, which encodes for a GAP protein, positioned as a
regulatory ‘hub’ in the pathways linking LRRK2 with PINK1
and DJ-1 (Fig. 1B).
Our results allow an interesting comparison to a screen for
LRRK2 interactors using a protein array performed by the
Cookson group (55). Our work appears to identify many more
kinases than the protein array work, while the protein array
work identified more small GTPases (Rabs) (55). This might
reflect difference in approaches. Transcriptome studies can iden-
tify interactions between proteins that bind only transiently, such
as kinases, and interactions that are linked in similar pathways,
but are physically indirect. Binding studies, though, will identify
direct binding interactions that do not lead to changes in gene
regulation. Combining the two approaches provides for a com-
prehensive overview of LRRK2 function.
RGS proteins are a family of proteins characterized by a GAP
domain of 130 amino acids, termed RGS domain. They have
been primarily described as regulators of GPCR-mediated sig-
naling. GPCRs transduce extracellular signals into downstream
intracellular effects via heterotrimeric G proteins, which shuttle
between an active GTP-bound and inactive GDP-bound form.
RGS proteins promote termination of the signal by accelerating
the intrinsic GTPase activity of Ga subunits of G proteins,
returning the G protein in its inactive GDP-bound form to the re-
ceptor (56). The specificity of the interaction of RGS2 with G
proteins in cells is determined by selective recognition of the
linked GPCR via its N-terminal domain (48). Here, we report
the non-canonical interaction of RGS2 via its catalytic GAP
domain with LRRK2 in vitro and in vivo. We identify RGS2 as
a novel GAP for the GTPase activity of LRRK2 in vitro. RGS2
also inhibits the kinase activity of LRRK2. Analysis of the
dose–response curves for RGS2 modulation of LRRK2 enzym-
atic activities shows that RGS2 achieves maximal inhibition of
LRRK2 kinase activity (50% inhibition) at a dose of RGS2
that is at least one-tenth the dose required to maximally stimulate
GTPase activity (i.e. RGS2:LRRK2 ratios of 1 versus .10,
Fig. 5D versus Fig. 5A). These data suggest that RGS2 affects
kinase activity of LRRK2 independently of its effects on GTPase
activity. Our studies of LRRK2 autophosphorylation show results
consistent with this hypothesis because co-expressing LRRK2
with RGS2 reduces phosphorylation of LRRK2 Serine 910.
These findings are consistent with experiments showing that
addition of guanine nucleotides directly to immunopurified
LRRK2 has no effect on kinase activity (6,57). We further
show in this study that the oligomerization of LRRK2 and
stability of the kinase-active dimer is similar in the presence or
absence of RGS2. We therefore propose a model in which
binding of RGS2 to LRRK2 induces local conformational
changes that directly inhibit kinase activity, independently of
effects on GTP hydrolysis.
We also identify RGS2 as a robust substrate for phosphoryl-
ation by LRRK2 in vitro. Phosphorylation of RGS2 has once
previously been reported (58). Intriguingly, in that study, the
authors demonstrate a phosphorylation-dependent inhibition of
the GAP activity of RGS2 by Protein Kinase C, as part of the
Figure 8. Levels of RGS2 are reduced in mutant G2019S LRRK2 and sporadic PD brains. Immunoblots of endogenous RGS2 levels in caudate striatal lysates from
human G2019S LRRK2 PD patients and neurologic controls (A) or human sporadic PD patients and neurologic controls (B). Normalization to actin levels reveals that
RGS2 levels in PD patients are significantly reduced (∗P, 0.05, ∗∗P, 0.01, Student’s unpaired t-test) compared with controls. Bars represent mean+SEM.
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inositol lipid signaling pathway. Provided sufficient amounts of
recombinant phosphorylated RGS2 can be obtained, future
studies would aim to determine whether phosphorylation by
LRRK2 also affects the GAP activity of RGS2, as part of a
feedback mechanism. It will also be important to ascertain
whether RGS2 represents an authentic physiological substrate
of LRRK2 in vivo. Future mapping of phosphorylation sites
and generation of phospho-mimic and phospho-deficient forms
of RGS2 should clarify the role of LRRK2-mediated phosphor-
ylation on RGS2 activities.
The discovery of RGS2 as modulator of LRRK2 activity may
provide valuable clues about upstream signaling events poten-
tially controlling LRRK2-dependent neuronal phenotypes in
the brain. Indeed, very little is known about such events, espe-
cially in the striatum, which is particularly relevant to PD and
where both LRRK2 and RGS2 are abundantly expressed
(50,49). We observed significantly reduced protein levels of
RGS2 in the striatum of both G2019S LRRK2 and sporadic
PD patients. Previous experiments have shown that administra-
tion to rats of the 6-OHDA toxin, which causes a targeted loss of
nigrostriatal dopaminergic projections, fails to induce changes
in striatal RGS2 levels (59). Therefore, the reduction in striatal
RGS2 levels in PD patients is unlikely to be due to the simple
loss of dopaminergic projections that occurs in PD. Rather,
striatal RGS2 expression has been shown to be dynamically re-
sponsive to neuronal activity with RGS2 mRNA being rapidly
and selectively upregulated in the striatum in response to
plasticity-inducing synaptic stimuli such as amphetamine (60)
or haloperidol (61). This dynamic gene expression pattern is
thought to be specifically mediated by dopamine D1 and D2
receptors (62). Changes in DA receptor responsiveness occur
in PD as a consequence of striatal DA depletion and may
explain the significantly reduced levels of RGS2 we measured
in the striatum of PD patients. These findings therefore raise
the intriguing possibility that LRRK2 activity may be regulated
by dopamine-dependent mechanisms in the striatum, via its re-
sponse to fluctuating cellular levels of RGS2. Interestingly, we
show that knockdown of RGS2 leads to LRRK2-dependent
neurite retraction in primary neurons. Reduced striatal levels
of RGS2 may therefore lead to neurite shortening via LRRK2
and potentially contribute to exacerbate neurodegeneration in
G2019S LRRK2 and sporadic PD.
Our study also identifies RGS2 as a potential therapeutic
target for treatment of PD caused by mutations in LRRK2.
Indeed, we show that overexpression of RGS2 protects against
neuronal toxicity induced by mutant G2019S LRRK2 in primary
neurons. As described below, we suggest that this protection is
mediated by RGS2 inhibition of LRRK2 kinase activity, which
would counteract the hyper-kinetic effects of the G2019S muta-
tion (17,19). Because of the biological and pharmaceutical
importance of GPCR signaling pathways (almost a third of
drugs on the market target GPCR receptors), significant
advances have already been made towards the development of
allosteric activators of RGS protein action (64). If specifically
tailored to target RGS2, our findings suggest that such com-
pounds may be neuroprotective in PD.
In addition to showing that RGS2 overexpression protects
against LRRK2-induced neurite shortening, we also find that
silencing of RGS2 induces neurite shortening in a LRRK2-
dependent manner and has a significant synergistic effect on
LRRK2-induced neurite shortening. Taken together, these find-
ings suggest that RGS2 and LRRK2 act in the same pathway
to regulate neurite length in primary neurons. Furthermore, if
RGS2 were acting downstream of LRRK2 in this pathway,
then the effect of RGS2 silencing on neurite length would be in-
dependent of the presence of LRRK2. Rather, our results are con-
sistent with RGS2 acting upstream to modulate LRRK2’s
function in the control of neurite length. We next sought to estab-
lish whether RGS2 required LRRK2 kinase activity to modulate
LRRK2-induced neurite shortening. We show that RGS2 silen-
cing has a significant synergistic effect on WT LRRK2-induced
neurite shortening. In contrast, loss of RGS2 expression fails to
produce a synergistic shortening of neurites in combination with
the kinase-inactive K1906M LRRK2 mutant. Since recombin-
ant RGS2 inhibits LRRK2 kinase activity in in vitro enzyme
activity assays, by combining our biochemical and functional
data, we propose a model in which RGS2 regulates LRRK2
function in the control of neurite length by modulating
LRRK2 kinase activity (Fig. 9). This model is supported by
our finding that neurite shortening induced by overexpression
of WT LRRK2 is rescued by genetic inhibition (K1906M mu-
tation) of LRRK2 kinase activity (WT LRRK2 versus K1906M
LRRK2, Fig. 7C versus Fig. 7D). Previous observations have
also shown that neurite shortening and toxicity induced by
the hyper-kinetic G2019S mutant are dependent on kinase ac-
tivity (17,19,53). We propose that overexpression of RGS2
protects against neurite shortening and toxicity induced by
G2019S LRRK2 by inhibiting kinase activity, thereby coun-
teracting the hyper-kinetic effects of the G2019S mutant
(Fig. 9). From the analysis of our LRRK2 GTPase and kinase
activity dose–response curves described above, we further
showed that RGS2 regulates kinase activity independently of
GTPase activity. Our model therefore suggests that the
GTPase domain has no functional role in mediating the
effects of RGS2 on the phenotypic output of LRRK2. This
model is strengthened by the finding that RGS2 does not influ-
ence in any meaningful way the steady-state levels of GTP-
bound LRRK2 in vivo (Fig. 5B). GTP hydrolysis activity of
LRRK2 has indeed been shown to be very low compared
with that of small GTPases (e.g. ras is 10-fold more active
than LRRK2 under identical assay conditions) (14,16).
In summary, we use a reverse-engineered gene regulatory
network to identify the signaling gene RGS2, encoding for a
GAP protein, as a ‘hub’ linkingLRRK2with other PD-associated
genes. Our data show that RGS2 modulates both the GTPase and
kinase activities of LRRK2. We identify a novel cellular func-
tion for RGS2 in the regulation of neuronal process length via
modulation of LRRK2 activity. This non-canonical role of
RGS2 is distinct from its function in regulating G-protein
mediated signaling. We demonstrate a protective effect of
RGS2 against toxicity induced by the prevalent PD-associated
G2019S mutation in LRRK2. Our data support a model in
which RGS2 regulates LRRK2 function and neuronal toxicity
through its effects on kinase activity and independently of
GTPase activity. This work strongly supports the hypothesis
that the kinase activity is the primary enzymatic output of
LRRK2 and reveals a novel mode of action for RGS proteins in-
dependently of their established GAP domain function. It also
identifies RGS2 as a potential target for interfering with neurode-
generation due to LRRK2 mutations in PD patients.
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MATERIALS AND METHODS
Systems biology analysis
PD patient microarray data were collected from the NCBI GEO
databases (http://www.ncbi.nlm.nih.gov/geo/) entries GSE8397
and GSE6613. These data sets contain microarray expression
data of 47 PD and control cases post mortem brain SNpc and
frontal cortex tissue samples from GSE8397 (29) and 72 PD
and control cases whole blood samples from GSE6613 (30), re-
spectively. All the raw .CEL files were downloaded and gene
expression levels were normalized with the robust multichip
average (RMA) algorithm. Gene set enrichment analysis was
performed to identify gene sets associated with PD (http://
www.broadinstitute.org/gsea/index.jsp). The 2776 genes in
these gene sets, which included LRRK2, were then used as
input for reverse-engineering the PD gene regulatory network
using the CLR algorithm, and the Mode of Action by Network
Identification (MNI) algorithm (28,65). The CLR algorithm esti-
mates a likelihood of the mutual information (MI) score for a par-
ticular pair of genes, i and j, by comparing the MI value for that
pair of genes to a background distribution of MI values (the null
model). The background distribution is constructed from two
sets of MI values: (MIi), the set of all the mutual information
values for gene i (in row or column i), and (MIj), the set of all
the mutual information values for gene j (in row or column j)
(28). Because biological regulatory networks are sparse, most
MI scores in each row of the mutual matrix represent random
background MI (e.g. due to indirect network relationships).
CLR approximates this background MI as a joint normal distribu-
tion with MIi and MIj as independent variables, which provides a
reasonable approximation to the empirical distribution of mutual
information. Thus, the final form of the CLR likelihood estimate
becomes f (Zi, Zj) =
NameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMe
Z2i + Z2j
√
, where Zi and Zj are the
Z-scores of MIij from the marginal distributions, and f(Zi, Zj) is
the joint likelihood measure. The likelihood of mutual informa-
tion for a particular pair of genes is considered significant when
f(Zi, Zj) ≥ 2.0. The CLR algorithm was implemented in Matlab
code, and the software package can be downloaded at http
://www.bu.edu/abl/data_and_software.html.
Expression plasmids, proteins and antibodies
Mammalian expression plasmids containing FLAG-tagged
full-length human LRRK2 (WT, R1441C, Y1699C, G2019S
and D1994N) and FLAG-tagged human LRRK2 deletion
mutants were kindly provided by Dr Christopher Ross (Johns
Hopkins University, Baltimore, MD, USA) (19). N-terminal
2X-Myc-tagged full-length human LRRK2 plasmids (WT,
R1441C, G2019S and K1906M) were kindly provided by Dr
Mark Cookson (National Institutes of Health, Bethesda, MD,
USA) (17). Full-length N-terminal 3X-HA-tagged human RGS2
was purchased from Missouri S&T cDNA Resource Center
(plasmid #RGS020TN00); C-terminal HA-tagged truncated
human RGS2 lacking the first 78 amino acids (DN-RGS2) was
kindly provided by Dr John Hepler (Emory University, Atlanta,
GA, USA) (48) and the N-terminal HA-tagged full-length
mouse RGS2 was kindly provided by Dr Luc de Vries (Pierre
Fabre Research Institute, Castres, France) (64). Empty vector
control pcDNA 3.1+ plasmid was obtained from Invitrogen,
and pEGFP-N2 from Clontech (Mountain View, CA, USA).
shRNA sequences in lentiviral plasmid pLKO.1 targeting
mouse RGS2 (sh-RGS2 #1, TRCN0000034444; sh-RGS2 #2,
TRCN0000034445; sh-RGS2 #3, TRCN0000034446; sh-RGS2
#4, TRCN0000054758; sh-RGS2 #5, TRCN0000054759) were
obtained from Thermo Fisher Scientific (Open Biosystems,
Huntsville, AL, USA). shRNA targeting mouse LRRK2 (sh-
LRRK2, TRC0000022656) was obtained from Sigma-Aldrich
(St Louis, MO, USA). This shRNA was previously validated for
silencing of endogenous mouse LRRK2 in reference (54). A non-
silencing scramble control shRNA sequence in lentiviral plasmid
pLKO.1 was purchased from Addgene (plasmid #1864) (66). The
GST-tagged full-length human RGS2 protein was obtained from
Novus Biologicals (Littleton, CO, USA). LRRKtide peptide
(RLGRDKYKTLRQIRQ) was obtained from Invitrogen. The
following antibodies were employed: mouse monoclonal
anti-FLAG (M2), anti-FLAG-(M2)-peroxidase (Sigma-Aldrich,
Buchs, Switzerland); mouse monoclonal anti-c-myc (clone
9E10) (Roche Applied Science, Bradford, CO, USA); mouse
monoclonal anti-HA (HA.11) (Covance, Princeton, NJ, USA);
rabbit monoclonal anti-HA (#3724) (Cell Signaling Technology,
Danvers, MA, USA); goat anti-actin (MAB1501) (Millipore,
Billerica, MA, USA); rabbit polyclonal anti-RGS2 (sc-9103)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); rabbit poly-
clonal anti-RGS2 (GWB 68126D) (GenWay Biotech, San
Diego, CA, USA); rabbit polyclonal anti-GFP (A11122) (Invitro-
gen); rabbit polyclonal anti-LRRK2 [MJFF2 (c41-2)] (ab133474)
(Abcam, Cambridge, MA, USA); mouse monoclonal anti-
pSer910 LRRK2 (UDD1, Epitomics, Burlingame, CA, USA),
mouse monoclonal anti-pSer935 LRRK2 (UDD2, Epitomics,
Burlingame, CA, USA), peroxidase-coupled anti-mouse and anti-
rabbit IgG secondary antibodies, donkey anti-mouse and anti-
rabbit IgG coupled to AlexaFluor-488, and -594, and donkey
Figure 9.Model of the regulation by RGS2 of LRRK2 function in the control of neurite length. Binding of RGS2 to LRRK2 (i.e. RGS2 overexpression in our experi-
mental set-up) inhibitsLRRK2kinase activity,protecting againstneurite shortening inducedby LRRK2overexpression and resulting in maintenance of neurite length.
In contrast, loss of RGS2 binding (i.e. RGS2 silencing) enhances kinase activity, inducing neurite retraction. For clarity purposes, LRRK2 kinase activity is illustrated
here as autophosporylation.
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anti-mouse IgG coupled to DyLight-405 were all obtained from
Jackson Immuno Research (West Grove, PA, USA).
Cell culture and transient transfection
HEK293FT cells were maintained at 378C in a 5% CO2 atmos-
phere in Dulbecco’s modified Eagle’s medium (Invitrogen) sup-
plemented with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA, USA) and 1× penicillin/streptomycin.
For transient transfection, cells were transfected with plasmid
DNAs using FuGENE HD reagent (Roche Applied Science) or
Lipofectemine (Invitrogen) according to the manufacturer’s
instructions. Cells were routinely harvested at 48–72 h
post-transfection for western blot analysis and biochemical
assays.
Lentivirus production
LV were produced in HEK-293T cells using a third-generation
packaging system by calcium phosphate transfection with the
following plasmids: pCMV-D8.92 (13 mg), pRSVRev
(3.75 mg), pMD2.G (3 mg) and pLKO.1 vector containing
shRNA sequence (13 mg) (67). After 72 h, the medium was col-
lected and centrifuged in a SW32Ti ultracentrifuge rotor at 19
000 rpm for 90 min at 48C. The pellet was resuspended in
1.5 ml of buffer containing 1× phosphate-buffered saline
(PBS) pH 7.4 and 0.5% BSA for a 100× concentrated virus
stock. Viral titer was determined using the HIV-1 p24 antigen
ELISA kit (Zeptometrix Corp., Buffalo, USA). A p24 of 8 ng/ml
media was used for infecting primary cortical neurons at
a density of 133 000 cells in 1.5 ml media (per well of a 12-well
dish).
Co-IP assay and western blot analysis
For co- IP assays, HEK-293FT cells were transiently transfected
with each combination of plasmids in 10 cm dishes. After 48 h,
confluent cells were harvested in 1 ml of IP buffer [1× PBS pH
7.4, 1% Triton X-100, 1× phosphatase inhibitor cocktail 1 and 2
(Sigma-Aldrich), 1× Complete Mini protease inhibitor cocktail
(Roche Applied Sciences)]. Cell lysates were rotated at 48C for
1 h and soluble fractions were obtained by centrifugation at 17
500g for 15 min at 48C.
For in vitro pull-down assays with anti-FLAG, soluble
fractions were combined with 50 ml protein G-Dynabeads
(Invitrogen) pre-incubated with mouse anti-FLAG (5 mg;
Sigma-Aldrich) antibody followed by overnight incubation at
48C. Dynabead complexes were sequentially washed once
with IP buffer supplemented with 500 mM NaCl, twice with IP
buffer and three times with PBS. Immunoprecipitates were eluted
by heating at 708C for 10 min in 2× Laemmli sample buffer
(Bio-Rad AG, Reinach, Switzerland) with 5% 2-mercaptoethanol.
IPs and inputs (1% total lysate) were resolved by SDS–PAGE,
transferred to Protran nitrocellulose (0.2 mm; Perkin Elmer,
Schwerzenbach, Switzerland), and subjected to western blot
analysis with appropriate primary and secondary antibodies.
Proteins were visualized by enhanced chemiluminescence
(ECL; GE Healthcare, Glattbrugg, Switzerland) on a FujiFilm
LAS-4000 Luminescent Image Analysis system.
For in vitro pull-down assays with anti-HA, pre-cleared
soluble fractions were incubated overnight at 48C with monoclo-
nal mouse anti-HA (HA.11; Covance) followed by incubation
for 2 h at 48C with 50 ml rec-Protein G-Sepharose 4B beads
(Invitrogen) previously blocked with 1% BSA. Sepharose bead
complexes were sequentially washed three times with IP buffer.
Immunoprecipitates were eluted by heating at 708C for 10 min
in 1× NuPAGE LDS Sample Buffer and 1× NuPAGE Sample
Reducing Agent (Invitrogen). IPs and inputs were resolved
by SDS–PAGE, transferred to PVDF membranes (Bio-Rad,
Hercules, CA, USA), and subjected to western blot analysis with
appropriate primary and secondary antibodies. Proteins were
visualized by enhanced chemiluminescence (ECL; GE Health-
care, Pittsburgh, PA, USA) on a Bio-Rad ChemiDocTM XRS+
Luminescent Image Analysis system (Hercules, CA, USA).
For in vivo co-IP, protein extracts were prepared from the
cerebral cortex of adult wild-type mice by homogenization in
TNE buffer [10 mM Tris–HCl pH 7.4, 150 mM NaCl, 5 mM
EDTA, 0.5% NP-40, 1× phosphatase inhibitor cocktail 1 and
2 (Sigma-Aldrich), 1× Complete Mini protease inhibitor cock-
tail (Roche Applied Sciences)]. Protein concentration was deter-
mined by BCA assay (Pierce Biotechnology, Rockford, IL,
USA). Brain extracts were incubated overnight at 48C with poly-
clonal rabbit anti-LRRK2 (MJFF-2/c41-2; Abcam) or normal
rabbit IgG (sc-2027; Santa Cruz), followed by incubation for
2 h at 48C with 50 ml TrueBlot anti-Rabbit Ig IP Beads [Rabbit
TrueBlotw Set (with IP beads)-88-1688-31, Rockland, Gilberts-
ville, PA, USA). Bead complexes were sequentially washed
twice with TNE buffer and twice with TBS buffer (10 mM
Tris–HCl pH 7.4, 150 mM NaCl). Immunoprecipitates were
eluted by heating at 708C for 10 min in 1× NuPAGE LDS
Sample Buffer and 1× NuPAGE Sample Reducing Agent (Invi-
trogen). IPs and inputs were resolved by SDS–PAGE, trans-
ferred to PVDF membranes (Bio-Rad, Hercules, CA, USA),
and subjected to western blot analysis as above except that anti-
rabbit IgG HRP TrueBlot (Rockland) was used as a secondary
antibody for detection of RGS2. TrueBlot preferentially
detects the non-reduced form of rabbit IgG over the reduced,
SDS-denatured form of IgG, enabling detection of immuno-
blotted RGS2 target protein band (25 kDa), without hindrance
by interfering immunoprecipitating immunoglobulin light
chains.
Native PAGE/SDS–PAGE analysis
HEK293T cells were transiently transfected with each combin-
ation of plasmids in six-well plates. After 48 h, confluent cells
were gently washed once with ice-cold PBS, then harvested
using a cell scraper in native lysis buffer [PBS pH 7.4, 1× pro-
tease and phosphatase inhibitors (Roche Applied Science)],
lysed by four cycles of freezing and thawing, and centrifuged
at 17 500 g for 10 min. Protein concentration of cleared lysates
was determined by the BCA assay (Pierce, Thermo Scientific).
Equal amounts of proteins for each sample were loaded on a
NativePAGE Novex 3–12% Bis–Tris gel (Invitrogen) or com-
bined with 1× NuPAGE LDS sample buffer and 1× NuPAGE
Sample Reducing Agent (Invitrogen) before loading on a
NuPAGE Novex SDS–PAGE Bis–Tris gel (Invitrogen). Over-
night transfer to PVDF membranes at 48C was carried out,
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followed by western blot analysis with anti-myc and anti-HA anti-
bodies and visualization using enhanced chemoluminescence.
Postmortem human tissues samples
Postmortem human caudate tissue samples were provided by the
UCL brain bank (London, UK). The average ages (years) and
postmortem intervals (h)+STDEV for each set of samples
were: control PD: 82.7+ 13.3, 31.2+ 9.2, n ¼ 6; PD: 77.8+
4.0, 29.2+ 14.0, n ¼ 6; control G2019S: 86.7+ 9.3, 33.4+
10.1, n ¼ 3; G2019S PD: 81.7+ 2.1, 30.5+ 14.8, n ¼ 3. The
samples were homogenized as 20% (w/v) homogenates in low
salt 20 mM Tris pH 7.4 buffer, containing 0.5% Triton X-100,
1 mM EDTA, 1 mM trichostatin, 5 mM nicotinamide, 1× phos-
phatase inhibitor cocktail 1 and 2 (Sigma-Aldrich) and 1X Com-
plete Mini protease inhibitor cocktail (Roche Applied Sciences).
Total homogenates were subsequently cleared by centrifugation
at 10 000 g for 10 min at 48C.
GTP binding assay
HEK293T cells in 10 cm plates transiently expressing
myc-tagged LRRK2 variants in the presence or absence of
HA-RGS2 were lysed in 1 ml of lysis buffer G [1× PBS pH
7.4, 1% Triton X-100, 1× phosphatase inhibitor cocktail 1 and
2 (Sigma-Aldrich), 1× Complete Mini protease inhibitor cock-
tail (Roche Applied Sciences)], rotated for 1 h at 48C and clari-
fied by centrifugation at 17 500g for 10 min at 48C. Soluble
proteins were incubated with 50 ml g-aminohexyl-GTP-sephar-
ose bead suspension (Jena Bioscience, Jena, Germany) by rotat-
ing for 2 h at 48C. Beads were washed three times with buffer
G and once with PBS alone. For GTP competition assays, incu-
bation was allowed to proceed for 60 min at 48C, GTP was added
to a final concentration of 2 mM and incubation was continued
for a further 60 min at 48C followed by washing. GTP-bound
proteins were eluted in 1× NuPAGE LDS sample buffer and
1× NuPAGE Sample Reducing Agent (Invitrogen) by heating
at 708C for 10 min. GTP-bound proteins or input lysates (1%
total lysate) were resolved by SDS–PAGE and subjected to
western blotting with anti-myc and anti-HA antibodies.
GTP hydrolysis assay
The GTPase assay was conducted in buffer containing 20 mM
Tris (pH7.4), 50 mM NaCl, 10 mM MgCl2, 1 mM DTT, 0.5 mg/
ml BSA, 200 mm GTP and 3 mCi [a–
33P]-GTP. Recombinant
full-length human RGS2 (Abcam) was pre-incubated at various
concentrations with 32 nM of immunopurified full-length WT
LRRK2 (18) to give ratios of [RGS2]/[LRRK2]: 10, 5, 2.5, 1.3
and 0. The reactions were conducted in triplicate, initiated
by the addition of LRRK2 and incubated at room temperature
for 20 min. The reaction was stopped by the addition of 20 mM
EDTA, and the product [a–33P]-GDP was separated from
[a–33P]-GTP by PEI-cellulose thin layer chromatography
(Sigma-Aldrich), developed by 0.5 M KH2PO4 (pH 3.4) develop-
ing buffer and analyzed by scintillation counter. Background
reaction was conducted in the absence of LRRK2.
Kinase activity assay
Thekinase assay for LRRK2-catalyzed LRRKtide (RLGRDKYK
TLRQJRQ) phosphorylation was conducted in buffer containing
20 mM HEPES (pH 7.4), 50 mM NaCl, 10 mM MgCl2, 1 mM DTT,
0.5 mg/ml BSA, 1 mM beta-Gly-PO4, 100 mM LRRKtide, 100 mM
ATP and 1 mCi [g–
33P]-ATP. Recombinant full-length human
RGS2 (Abcam) was pre-incubated at various concentrations
with 100 nM of immunopurified full-length WT LRRK2 (18) to
give ratios of [RGS2]/[LRRK2]: 5, 2.5, 1.3, 0.6 and 0. The reac-
tions were conducted in duplicate, initiated by the addition of
LRRK2 and incubated at room temperature for 45 min. The reac-
tion was stopped by the addition of 20 mM EDTA, and the
mixtures were transferred to a multiscreen PH filtration plate
(Millipore) and washed six times with 75 mM H3PO4. The plate
was dried, filters were removed and the samples were counted
with a scintillation counter. Background reaction was conducted
in the absence of LRRK2.
RGS2 phosphorylation assay
HEK-293T cells were plated at high density in 10 cm dish plates
and transfected with (10 mg) FLAG-tagged LRRK2 DNA
(WT, G2019S and D1994A) and a mock control (pcDNA3.1).
Forty-eight hours post-transfection, cells were harvested and
lysed in 1 ml IP buffer [Tris–HCl 20 mM pH 7.5, NaCl
150 mM, EDTA 1 mM pH 8, Tween-20 1%, phosphatase
inhibitors 2 and 3 (Sigma-Aldrich) and 1× Complete protease
inhibitor cocktail (Roche Applied Sciences)] and centrifuged
at 17 500g for 15 min. Cleared lysates were incubated over-night
with 60 ml of M2-FLAG resin and complexes were washed five
times with Tris–HCl 20 mM pH 7.5, Tween-20 0.5% and NaCl
from 500 to 150 mM. This procedure was repeated twice.
Finally, M2-FLAG complexes were re-suspended in 1× kinase
buffer (25 mM Tris–HCl pH 7.5, 5 mM b-glycerophosphate,
2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2). LRRK2
proteins were eluted with 3xFLAG peptide as per manufac-
turer’s instructions (Cat.N.F4799) from M2-FLAG resin.
Recombinant commercially purified full-length GST-tagged
human RGS2 (Novus Biologicals) was used in this experiment
and for the kinase reactions 1 mg of purified RGS2 protein was
combined together with equal amount of eluted LRRK2.
In vitro kinase reactions were then performed in kinase buffer
(5 mM EGTA and 20 mM b-glycerol phosphate in PBS) in the
presence of [33P]-g-ATP (2 mCi/reaction; Perkin Elmer, MA,
USA) and 5 mM cold ATP (Sigma-Aldrich) at 308C for 1 h in a
final volume of 25 ml. The assays were terminated using 4×
Laemmli buffer and by boiling at 708C for 10 min. Complexes
were resolved on 4–16% SDS–PAGE pre-cast gels (Invitrogen)
and transferred to PVDF membranes. Incorporated radioactivity
was detected by autoradiography and the same membranes were
probed with anti-GST and anti-FLAG antibodies for protein
loading control.
Immunocytochemistry and confocal microscopy
For co-localization of overexpressed myc-LRRK2 and HA-
RGS2, HEK293T cells or primary cortical neurons transiently
expressing myc-LRRK2 and HA-RGS2 were fixed in 4% paraf-
ormaldehyde (PFA) for 10 min at room temperature and
4902 Human Molecular Genetics, 2014, Vol. 23, No. 18
immunolabeled with mouse anti-myc (Roche) and rabbit
anti-HA (Cell Signaling) antibodies, followed by donkey anti-
mouse AlexaFluor-594 and donkey anti-rabbit AlexaFluor-488
secondary antibodies (Jackson Immuno Research). Confocal
microscopy was performed on an upright Carl Zeiss LSM 510
META confocal microscope (Carl Zeiss Microscopy) using
63× high numerical-aperture oil immersion objective lenses.
Image size was set to 1024 × 1024 pixels. Between 12–15 and
18–20 optical slices for primary neurons and HEK293T cells re-
spectively were collected through the z plane with a 0.5 mm step
between each slice. All images were processed using ImageJ
software. Images shown are taken from a single z-plane (XY
slice) with additional orthogonal views of XZ and YZ slices
along the indicated lines of the z-stack obtained using the
Stacks  Orthogonal Views option on ImageJ.
For co-immunolabeling of triple-transfected neurons, fixed
GFP-positive transfected neurons were immunolabeled with
mouse anti-myc and rabbit anti-HA, followed by anti-rabbit
IgG-AlexaFluor-488 and anti-mouse IgG-DyLight-405 anti-
bodies. Images were acquired using an upright Carl Zeiss LSM
510 META confocal microscope.
Primary neuronal cultures
Whole brains were dissected from CD-1 P0 mice and the cerebral
cortices were stereoscopically isolated and dissociated in media
containing papain (20 U/ml; Sigma). The cells were grown in
12-well plates on glass cover slips pre-coated with mouse
laminin (33 mg/ml; Invitrogen) and poly-D-lysine (20 ng/ml;
BD Biosciences, San Jose, CA, USA) in media consisting of
Neurobasal (Invitrogen), B27 supplement (2% w/v), L-glutamine
(500 mM) and penicillin/streptomycin (100 U/ml). At DIV3, cor-
tical cultures were treated with cytosine b-D-arabinofuranoside
(AraC, 2 mM) to inhibit glial cell division. No change of
medium was made during the course of the experiment.
Neurite length assay
For co-expression experiments, primary cortical cultures
at DIV5 were co-transfected with pcDNA3.1(Control) or myc-
LRRK2, pcDNA3.1 or HA-RGS2 and GFP plasmids at a 10:
10:1 molar ratio (2 mg total DNA per well) using Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s
recommendations. At DIV20, cultures were fixed with 4%
PFA and processed for immunocytochemistry with rabbit
anti-GFP and mouse anti-MAP2 antibodies, followed by anti-
rabbit IgG-AlexaFluor-488 and anti-mouse IgG-AlexaFluor-
594 antibodies.
For assays using shRNA plasmids, primary cortical cultures
at DIV5 were co-transfected with sh-scramble (pLKO.1) or
sh-RGS2 #3, sh-scramble or sh-RGS2 #3 or sh-LRRK2, and
GFP plasmids at a 10:10:1 molar ratio (1.6 mg total DNA per
well) using Lipofectamine 2000 reagent (Invitrogen). At
DIV20, cultures were fixed and immunolabeled as above.
For lentivirus silencing experiments, lentiviruses based on
pLKO.1 (LV-sh-scramble) and sh-RGS2 #3 (LV-sh-RGS2)
were used. Primary cortical cultures at DIV3 were infected with
LV-sh-scramble or LV-sh-RGS2 at a final dose of 8 ng of p24
antigen per ml of media, followed at DIV5 by co-transfection
of pcDNA3.1 or myc-LRRK2 and GFP plasmids at a 10:1 ratio
using Lipofectamine 2000 (Invitrogen). At DIV20, cultures
were fixed and immunolabeled as above. For each experiment,
n ¼ 30–45 individual GFP-positive neurons were randomly
selected. Fluorescent images were acquired using an upright
Olympus BX-60 equipped with epifluorescence optics and a
digital camera (AxioCam MRm; Carl Zeiss Microscopy) with
a 10× objective. The length of the longest MAP2-negative
neurite, corresponding to the axon, of each selected neuron was
measured using the line tool function of the NIH ImageJ software
by an investigator blinded to each condition. Only neurons with
processes at least twice the length of the cell body diameter were
selected. Camera lucida drawings were traced using the NeuroJ
plug-in of ImageJ (NIH). In cases where the length of the longest
neurite exceeded the dimensions of a single 10× photograph,
figures were reconstructed using Adobe Photoshop software.
Three independent experiments were carried out.
Neuronal toxicity assay
Fluorescent images of randomly selected fields of view were
acquired using an upright Olympus BX-60 equipped with epi-
fluorescence optics and a digital camera (AxioCam MRm;
Carl Zeiss Microscopy) with a 10× objective. For each experi-
ment, n ¼ 150–200 GFP-positive transfected neurons were
counted by an investigator blinded to each condition. Neurons
with no obvious processes or processes shorter than twice the
size of the cell body were counted as non-viable. The number
of viable transfected neurons was expressed as a percentage of
total transfected neurons counted in each experiment/culture.
Three independent experiments were carried out.
Statistical analysis
Analyses included one-way ANOVA with Newman–Keuls post
hoc testing for comparison of multiple data groups, and two-
tailed unpaired Student’s t-test for pair-wise comparisons, using
the GraphPad Prism program. Two-way factorial ANOVA with
the Newman–Keuls post hoc analysis was performed to demon-
strate the synergistic effect of RGS2 silencing on WT LRRK2
overexpression, using the Statistica software (Statsoft). P,
0.05 was considered significant. Error bars reflect SEM values.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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